Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Current Investments (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Cash & Current Investments data on record, last reported at $64.1 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 51.21% year-over-year to $64.1 million; the TTM value through Dec 2025 reached $64.1 million, down 51.21%, while the annual FY2025 figure was $64.1 million, 51.21% down from the prior year.
  • Cash & Current Investments reached $64.1 million in Q4 2025 per TGTX's latest filing, up from $59.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $523.8 million in Q1 2021 and bottomed at $59.3 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $228.0 million, with a median of $213.5 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: surged 568.73% in 2021, then plummeted 82.62% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $314.8 million in 2021, then tumbled by 48.64% to $161.7 million in 2022, then skyrocketed by 34.53% to $217.5 million in 2023, then tumbled by 39.55% to $131.5 million in 2024, then crashed by 51.21% to $64.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $64.1 million in Q4 2025, $59.3 million in Q3 2025, and $124.1 million in Q2 2025.